Q2 2026 VC Trends : Remote Patient Monitoring Systems (RPM)
Q2 2026 highlight: in the RPM market, venture capital (VC) transactions further distinguish between (i) standalone monitoring technologies and (ii) platforms that combine clinical data, workflow integration, intervention and a credible payment model.
This SRV review identifies valuation-relevant signals from selected recent transactions in the sector. It presents a public subset of the market analysis used in valuation work involving companies from Seed through Series C.
Sector reviewed : RPM
Remote patient monitoring systems are clinically directed products and platforms that repeatedly collect physiological or clinically relevant patient data outside conventional care settings and connect that information to clinical review, triage, treatment adjustment or longitudinal care management.
The sector includes connected medical devices and wearables, device-agnostic RPM platforms, virtual wards and integrated chronic-care systems in which remote monitoring is a central function.
For this review, exclusions include consumer wellness products without a defined clinical pathway, general telehealth, one-time diagnostics, pure EHR or clinical-AI software, home-care staffing platforms and therapeutic implants for which monitoring is incidental.
From expansion to selective financing
RPM developed within an exceptional digital-health capital cycle. U.S. digital-health venture funding increased from US$8.2 billion in 2019 to US$29.1 billion in 2021. It later reset to US$10.5 billion in 2024 before recovering to US$14.2 billion in 2025. During H1 2026, U.S. digital-health companies raised US$7.4 billion across 244 transactions, including US$3.2 billion during Q2. Nineteen companies completed 20 rounds of US$100 million or more, accounting for 45% of H1 capital. These figures describe digital health generally, not RPM alone.
Selected RPM transactions illustrate how valuation evidence changed within that cycle:
| Period | Key transaction evidence | Valuation signal |
|---|---|---|
| 2021–2022 expansion | Best Buy acquired Current Health for approximately US$400 million. Biofourmis then raised US$300 million at a reported US$1.3 billion valuation. | Virtual-care and integrated monitoring platforms attracted substantial strategic and growth capital. |
| 2023–2025 reset | Huma completed a Series D and related share issuances totalling more than US$80 million. Current Health was later reacquired by its co-founder on undisclosed terms. | Capital remained available for regulated platforms. Current Health’s divestiture shows that strategic fit can change; the undisclosed terms do not establish a resale valuation. |
| Q2 2026 | Cadence raised US$100 million. In adjacent metabolic health, Dexcom agreed to acquire Nutrisense on undisclosed terms. | Cadence reinforced the relevance of care delivery and institutional workflow. Dexcom–Nutrisense signalled interest in adding professional guidance and behavioural support to sensor data. |
Q2 2026: the clearest RPM financing signal
Cadence’s US$100 million Series C, led by Spark Capital, was the clearest valuation-relevant clinical RPM financing identified for the quarter. The company reported more than 100,000 active patients, relationships with more than 20 health systems and a tripling of annual recurring revenue during 2025. Health-system investors included Duke Health, Memorial Hermann and Corewell Health Ventures.
Cadence is not limited to collecting and displaying patient measurements. Its system integrates daily monitoring, supervised AI, clinical review, medication support and personalized intervention into health-system records and workflows. Cadence also cited peer-reviewed observational studies reporting fewer hospital admissions and lower Medicare costs among monitored patients. Those studies support an association, not proof of causation.
Dexcom’s agreement to acquire Nutrisense supplied an adjacent strategic signal rather than a core RPM financing event. If completed, the transaction would add registered-dietitian access, personalized nutrition guidance and behavioural support to Dexcom’s continuous glucose data. Financial terms were not disclosed.
What changed — and what did not
| Valuation factor | Q2 2026 assessment | Delta |
|---|---|---|
| Standalone monitoring or dashboard functionality | The selected Q2 transactions do not establish a material change in its valuation relevance. | No change established |
| Monitoring combined with clinical intervention | Central to the strongest RPM financing identified for the quarter. | Reinforced |
| Health-system and EHR integration | Supported by customer relationships and direct health-system participation in Cadence’s round. | Reinforced |
| Clinical and economic evidence | Explicitly emphasized in Cadence’s financing rationale and supported by observational studies. | Reinforced |
| Regulatory infrastructure | Remains relevant for device-led and configurable platform models, as illustrated by Huma’s prior financing. | Maintained |
| AI functionality by itself | Broader digital-health evidence indicates that AI is no longer independently differentiating; the selected RPM transactions do not quantify that effect. | Weaker as a broad claim |
| Reimbursement or value-based payment | A defined payment pathway was material to Cadence’s financing case; reimbursement durability and compliance remain material risks. | Reinforced, with risk |
These observations do not establish that proprietary sensors or medical-device intellectual property have lost importance. In the selected evidence, the surrounding clinical and commercial system was material to the financing rationale.
Valuation perspective
The selected Q2 2026 evidence reinforced an existing market segmentation rather than establishing a new RPM investment cycle. Integrated chronic-care platforms can still attract substantial institutional capital, while businesses sharing the RPM label may carry materially different regulatory, operating and commercialization risks.
SR Valuation Inc. (SRV) applies the Backward Valuation Method (BVM) to identify structurally relevant comparable companies, interpret their financing histories and normalize the resulting valuation evidence to an equivalent company stage.
Order a Benchmark Valuation Report (BVM Level 1) →
Methodology: This review considers selected financings, acquisitions and corporate developments because of their relevance to startup valuation. It is not an exhaustive inventory of RPM transactions, a sector investment report or investment advice.
Sources: Rock Health, 2021 Year-End Digital Health Funding: Seismic Shifts Beneath the Surface (January 10, 2022); Rock Health, 2025 Year-End Digital Health Funding Overview: A Tale of Two Markets (January 12, 2026); Rock Health, H1 2026 Funding and Market Overview: Durable Roots, Shifting Routes (July 13, 2026); Biofourmis, Biofourmis Receives Significant Growth Investment from General Atlantic to Surpass Unicorn Status (April 26, 2022), supplemented by MobiHealthNews coverage of the reported US$1.3 billion valuation; Huma, Huma Completes Series D with Total Financing of Over US$80 Million (July 16, 2024); Fierce Healthcare, coverage of Best Buy’s approximately US$400 million acquisition of Current Health (November 29, 2021); Healthcare Dive, coverage of Current Health’s 2025 divestiture (June 26, 2025); Cadence, Cadence Raises US$100 Million Series C Led by Spark Capital to Automate Chronic Care (June 23, 2026); Feldman et al., The Impact of a Remote Patient Care Program on Health Care Costs and Utilization Among Medicare Patients With Chronic Disease, Mayo Clinic Proceedings: Innovations, Quality & Outcomes (2025); and Dexcom, Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier-Stage Intervention and Preventative Care at ADA 2026 (June 4, 2026). Rock Health figures reflect its latest available dataset and may revise previously published historical totals. All sources were reviewed as available on July 17, 2026.
